Equities
  • Price (EUR)468.80
  • Today's Change9.50 / 2.07%
  • Shares traded0.00
  • 1 Year change+19.74%
  • Beta--
Data delayed at least 15 minutes, as of Mar 22 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Humana Inc. is a health and well-being company. The Company operates through two segments: Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly through group Medicare accounts. It also includes its contract with the Centers for Medicare and Medicaid Services (CMS) to administer the Limited Income Newly Eligible Transition (LI-NET), prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. The Insurance segment also includes products consisting of employer group commercial fully-insured medical and specialty health. The CenterWell segment represents its payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The Company’s subsidiaries include Mid-South Home Health Agency, LLC, Premier Home Health Agency, LLC and Humana Regional Health Plan, Inc.

  • Revenue in USD (TTM)92.87bn
  • Net income in USD2.81bn
  • Incorporated1964
  • Employees67.10k
  • Location
    Humana Inc500 W Main StLOUISVILLE 40202United StatesUSA
  • Phone+1 (502) 580-1000
  • Fax+1 (302) 636-5454
  • Websitehttp://www.humana.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HUM:NYQ since
announced
Transaction
value
Inclusa IncAnnounced12 Aug 202212 Aug 2022Announced2.95%--
Data delayed at least 15 minutes, as of Mar 22 2023 20:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.